Abstract
The presentation cytogenetic result was correlated with outcome for 999 patients with acute myeloblastic leukemia (AML) having bone marrow transplantation (BMT) in first complete remission (CR1). The karyotype at diagnosis was classified according to the modified Chicago classification. Allogeneic BMT (AlloBMT) was performed in 500 patients and autologous BMT (ABMT) in 499 patients. For both groups, an abnormal chromosome (abn) 5 and/or 7 or a hypodiploid karyotype had a poor outcome, whereas t(15;17), pseudodiploidy, hyperdiploidy and diploidy were associated with a standard prognosis. Abn (16) and t(8;21) were also of standard prognosis for ABMT, but favorable for AlloBMT. When comparing AlloBMT and ABMT in patients with favorable or standard cytogenetics, AlloBMT was of benefit for remission duration and leukemia-free survival (LFS). Patients with an unfavorable karyotype had a similar outcome, regardless of type of BMT. By multivariate analysis, cytogenetics at diagnosis had the strongest prognostic value for relapse, LFS, and survival in AlloBMT. In ABMT, cytogenetics influenced relapse and LFS. We concluded that the karyotype at diagnosis had important prognostic implication in AML grafted in CR1.
| Original language | English |
|---|---|
| Pages (from-to) | 2931-2938 |
| Number of pages | 8 |
| Journal | Blood |
| Volume | 90 |
| Issue number | 8 |
| Publication status | Published - Oct 15 1997 |
Fingerprint
ASJC Scopus subject areas
- Hematology
Cite this
Karyotype in acute myeloblastic leukemia : Prognostic significance for bone marrow transplantation in first remission: A European Group for Blood and Marrow Transplantation Study. / Ferrant, A.; Labopin, M.; Frassoni, F.; Prentice, H. G.; Cahn, J. Y.; Blaise, D.; Reiffers, J.; Visani, G.; Sanz, M. A.; Boogaerts, M. A.; Löwenberg, B.; Gorin, N. C.
In: Blood, Vol. 90, No. 8, 15.10.1997, p. 2931-2938.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Karyotype in acute myeloblastic leukemia
T2 - Prognostic significance for bone marrow transplantation in first remission: A European Group for Blood and Marrow Transplantation Study
AU - Ferrant, A.
AU - Labopin, M.
AU - Frassoni, F.
AU - Prentice, H. G.
AU - Cahn, J. Y.
AU - Blaise, D.
AU - Reiffers, J.
AU - Visani, G.
AU - Sanz, M. A.
AU - Boogaerts, M. A.
AU - Löwenberg, B.
AU - Gorin, N. C.
PY - 1997/10/15
Y1 - 1997/10/15
N2 - The presentation cytogenetic result was correlated with outcome for 999 patients with acute myeloblastic leukemia (AML) having bone marrow transplantation (BMT) in first complete remission (CR1). The karyotype at diagnosis was classified according to the modified Chicago classification. Allogeneic BMT (AlloBMT) was performed in 500 patients and autologous BMT (ABMT) in 499 patients. For both groups, an abnormal chromosome (abn) 5 and/or 7 or a hypodiploid karyotype had a poor outcome, whereas t(15;17), pseudodiploidy, hyperdiploidy and diploidy were associated with a standard prognosis. Abn (16) and t(8;21) were also of standard prognosis for ABMT, but favorable for AlloBMT. When comparing AlloBMT and ABMT in patients with favorable or standard cytogenetics, AlloBMT was of benefit for remission duration and leukemia-free survival (LFS). Patients with an unfavorable karyotype had a similar outcome, regardless of type of BMT. By multivariate analysis, cytogenetics at diagnosis had the strongest prognostic value for relapse, LFS, and survival in AlloBMT. In ABMT, cytogenetics influenced relapse and LFS. We concluded that the karyotype at diagnosis had important prognostic implication in AML grafted in CR1.
AB - The presentation cytogenetic result was correlated with outcome for 999 patients with acute myeloblastic leukemia (AML) having bone marrow transplantation (BMT) in first complete remission (CR1). The karyotype at diagnosis was classified according to the modified Chicago classification. Allogeneic BMT (AlloBMT) was performed in 500 patients and autologous BMT (ABMT) in 499 patients. For both groups, an abnormal chromosome (abn) 5 and/or 7 or a hypodiploid karyotype had a poor outcome, whereas t(15;17), pseudodiploidy, hyperdiploidy and diploidy were associated with a standard prognosis. Abn (16) and t(8;21) were also of standard prognosis for ABMT, but favorable for AlloBMT. When comparing AlloBMT and ABMT in patients with favorable or standard cytogenetics, AlloBMT was of benefit for remission duration and leukemia-free survival (LFS). Patients with an unfavorable karyotype had a similar outcome, regardless of type of BMT. By multivariate analysis, cytogenetics at diagnosis had the strongest prognostic value for relapse, LFS, and survival in AlloBMT. In ABMT, cytogenetics influenced relapse and LFS. We concluded that the karyotype at diagnosis had important prognostic implication in AML grafted in CR1.
UR - http://www.scopus.com/inward/record.url?scp=0030762673&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030762673&partnerID=8YFLogxK
M3 - Article
C2 - 9376573
AN - SCOPUS:0030762673
VL - 90
SP - 2931
EP - 2938
JO - Blood
JF - Blood
SN - 0006-4971
IS - 8
ER -